Rafael Franco Fernandez-rekin lankidetzan egindako argitalpenak (33)

2022

  1. Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APPswe Alzheimer’s Disease Mouse Model

    International Journal of Molecular Sciences, Vol. 23, Núm. 7

2019

  1. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model

    Frontiers in Immunology, Vol. 10, Núm. MAY

2018

  1. Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice

    Neuropsychopharmacology, Vol. 42, Núm. 2, pp. 524-539

  2. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

  3. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

    Neuropharmacology, Vol. 113, pp. 110-123

2016

  1. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease

    Brain, Behavior, and Immunity, Vol. 57, pp. 94-105

  2. Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors

    Molecular Neurobiology, Vol. 53, Núm. 4, pp. 2312-2319

  3. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

2015

  1. Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

    Clinical Epigenetics, Vol. 7, Núm. 1

  2. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

    Neuropathology and Applied Neurobiology, Vol. 41, Núm. 4, pp. 471-482

  3. Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins

    Trends in Biochemical Sciences

2014

  1. GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells

    Hippocampus, Vol. 24, Núm. 7, pp. 733-739

  2. Phosphodiesterase inhibition in cognitive decline

    Journal of Alzheimer's Disease, Vol. 42, pp. S561-S573

  3. Synthesis and evaluation of 13N-labelled azo compounds for β-amyloid imaging in mice

    Molecular Imaging and Biology, Vol. 16, Núm. 4, pp. 538-549

  4. The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model

    Neurobiology of Aging, Vol. 35, Núm. 11, pp. 2603-2616

2013

  1. Age-related mitochondrial alterations without neuronal loss in the hippocampus of a transgenic model of Alzheimer's disease

    Current Alzheimer Research, Vol. 10, Núm. 4, pp. 390-405

  2. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients

    Neurobiology of Aging, Vol. 34, Núm. 3, pp. 805-808

  3. Epigenetic drugs in Alzheimer's disease

    Biomolecular Concepts, Vol. 4, Núm. 5, pp. 443-445

  4. Phenyl Acyl Acids Attenuate the Unfolded Protein Response in Tunicamycin-Treated Neuroblastoma Cells

    PLoS ONE, Vol. 8, Núm. 8